Stocklytics Platform
Asset logo for symbol LTRN
Lantern Pharma
LTRN43
$3.26arrow_drop_down2.98%-$0.10
Penny Stock
Asset logo for symbol LTRN
LTRN43

$3.26

arrow_drop_down2.98%

Performance History

Chart placeholder
Key Stats
Open$3.30
Prev. Close$3.35
EPS-1.78
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$41.62M
PE Ratio-
LOWHIGH
Day Range3.20
3.52
52 Week Range2.38
11.99
Ratios
Revenue-
EBITDA Margin %-
EPS-1.78

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Lantern Pharma (LTRN)

Lantern Pharma Inc (LTRN) is a biotechnology company focused on using artificial intelligence (AI) and genomics to develop targeted cancer therapies. The company’s stock price history has been volatile, with fluctuations driven by news and updates related to its drug development pipeline. LTRN has shown promise in its early-stage clinical trials, and investors are closely watching its progress in bringing new drugs to market. LTRN quote can be found on various financial websites and platforms, providing up-to-date information on the stock's performance.
In recent news, Lantern Pharma Inc announced the successful completion of a Phase 1 clinical trial for its lead drug candidate. The results were encouraging, showing positive efficacy and safety profiles. This news led to a significant increase in LTRN's stock price, as investors recognized the potential of the drug in addressing unmet medical needs in certain cancer types. The company's stock analysis suggests that LTRN may be undervalued compared to its peers in the biotechnology industry.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Panna Sharma PH.D.
Headquarters
Dallas
Employees
22
Exchange
NASDAQ
add Lantern Pharma  to watchlist

Keep an eye on Lantern Pharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Lantern Pharma 's (LTRN) price per share?

The current price per share for Lantern Pharma (LTRN) is $3.26. The stock has seen a price change of -$0.1 recently, indicating a -2.99% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Lantern Pharma (LTRN)?

For Lantern Pharma (LTRN), the 52-week high is $11.99, which is 267.34% from the current price. The 52-week low is $2.38, the current price is 37.14% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Lantern Pharma (LTRN) a growth stock?

Lantern Pharma (LTRN) has shown an average price growth of -1.65% over the past three years. It has received a score of 29 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lantern Pharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Lantern Pharma (LTRN) stock price performance year to date (YTD)?

As of the latest data, Lantern Pharma (LTRN) has a year-to-date price change of 2.32%. Over the past month, the stock has experienced a price change of -5.39%. Over the last three months, the change has been -20.97%. Over the past six months, the figure is 5.97%.
help

Is Lantern Pharma (LTRN) a profitable company?

Lantern Pharma (LTRN) has a net income of -$15.96M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$17.88M. Furthermore, the EBITDA is -$21.18M.
help

What is the market capitalization of Lantern Pharma (LTRN)?

Lantern Pharma (LTRN) has a market capitalization of $41.63M. The average daily trading volume is 3.29, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level